Shares of Arbutus Biopharma Corp (NASDAQ:ABUS) have been assigned a consensus rating of “Hold” from the nine analysts that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $13.80.
A number of brokerages recently weighed in on ABUS. Chardan Capital reissued a “buy” rating on shares of Arbutus Biopharma in a report on Tuesday, January 16th. Zacks Investment Research lowered Arbutus Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, January 18th. BidaskClub upgraded Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, ValuEngine upgraded Arbutus Biopharma from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
A number of institutional investors and hedge funds have recently bought and sold shares of ABUS. BlackRock Inc. grew its position in Arbutus Biopharma by 7,615.3% during the 4th quarter. BlackRock Inc. now owns 751,314 shares of the biopharmaceutical company’s stock worth $3,794,000 after acquiring an additional 741,576 shares during the last quarter. Hudson Bay Capital Management LP grew its position in Arbutus Biopharma by 239.0% during the 4th quarter. Hudson Bay Capital Management LP now owns 400,000 shares of the biopharmaceutical company’s stock worth $2,020,000 after acquiring an additional 282,000 shares during the last quarter. Renaissance Technologies LLC grew its position in Arbutus Biopharma by 150.7% during the 4th quarter. Renaissance Technologies LLC now owns 402,573 shares of the biopharmaceutical company’s stock worth $2,033,000 after acquiring an additional 241,963 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Arbutus Biopharma during the 3rd quarter worth approximately $1,393,000. Finally, Eversept Partners LLC bought a new position in Arbutus Biopharma during the 4th quarter worth approximately $543,000. Institutional investors and hedge funds own 60.04% of the company’s stock.
Shares of Arbutus Biopharma (ABUS) traded up $0.35 during midday trading on Wednesday, hitting $5.65. The company had a trading volume of 172,700 shares, compared to its average volume of 176,566. The stock has a market cap of $291.78, a PE ratio of -1.14 and a beta of 1.12. The company has a current ratio of 11.03, a quick ratio of 11.03 and a debt-to-equity ratio of 0.08. Arbutus Biopharma has a 52 week low of $2.55 and a 52 week high of $8.25.
ILLEGAL ACTIVITY NOTICE: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/14/arbutus-biopharma-corp-abus-receives-average-rating-of-hold-from-brokerages.html.
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.